Metagenomi Inc

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene edit­ing toolbox, ther­a­peu­tic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.

NEW YORK--(BUSINESS WIRE)---- $MGX #Investigation--The law firm of Kirby McInerney LLP is investigating potential claims against Metagenomi, Inc. (“Metagenomi” or the “Company”) (NASDAQ: MGX). The investigation concerns whether Metagenomi and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On February 12, 2024, Metagenomi conducted its initial public offering (“IPO”), selling approximately 6.25.

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Metagenomi, Inc. (MGX)

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Metagenomi, Inc. (“Metagenomi” or the “Company”) (NASDAQ: MGX) investors concerning the Company's possible violations of federal securities laws. On February 12, 2024, Metagenomi conducted its initial public offering (“IPO”), selling approximately 6.25 million shares at $15 per share. However, on May 1, 2024, less than three months after the IPO, Metagenomi announced that it and Moderna had “m.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Metagenomi, Inc. (MGX) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Metagenomi, Inc. (“Metagenomi” or the “Company”) (NASDAQ: MGX) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On February 12, 2024, Metagenomi conducted its initial public offering (“IPO”), selling approximately 6.25 million shares at $15 per share. However, on May 1, 2024, less than.

The Law Offices of Frank R. Cruz Announces Investigation of Metagenomi, Inc. (MGX) on Behalf of Investors

EMERYVILLE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced that Metagenomi CEO and Founder, Brian C. Thomas, will present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:30 a.m. Eastern Time. The Company will also participate in one-on-one investor meetings at the conference taking place June 5-6.

Metagenomi to Present at the 2024 Jefferies Global Healthcare Conference

Late breaking presentation at World Federation of Hemophilia (WFH) World Congress on investigational development program in Hemophilia A; development candidate nomination anticipated in mid-year 2024; 12-month non-human primate durability data expected in 2H 2024

Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results

Global X Genomics & Biotechnology ETF

Intellia Therapeutics

Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion from $5.3 billion in 2023.

3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire

Enhances strategic flexibility and control of key gene editing technologies and programs Enhances strategic flexibility and control of key gene editing technologies and programs

Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems

-   Oral Presentation at World Federation of Hemophilia (WFH) World Congress,  April 23, 2024 -   Two Posters at American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, May 8 & 9, 2024 EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced that the Company will present at two upcoming scientific meetings: a late breaking oral presentation at The World Federation of Hemophilia (WFH) World Congress, taking place April 21 – 24, 2024 in Madrid, Spain and two poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

Metagenomi to Present at Upcoming Scientific Meetings

Demonstrated nonhuman primate proof of concept in Hemophilia A program; progressing towards Development Candidate nomination by mid-year; 12-month nonhuman primate durability data in 2H 2024

Metagenomi Reports Business Updates and Full Year 2023 Financial Results

EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Metageno­mi, Inc. (Nas­daq: MGX), a pre­ci­sion genet­ic med­i­cines com­pa­ny com­mit­ted to devel­op­ing cura­tive ther­a­peu­tics for patients using its pro­pri­etary, com­pre­hen­sive metage­nomics-derived gene edit­ing tool­box, today announced that Brian C. Thomas, CEO & Founder, will participate in a panel titled, “Emerging Genetic Therapy Approaches,” during the 44th Annual Cowen Healthcare Conference on Wednesday, March 6, 2024 from 12:50-1:50 PM ET in Boston.

Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference

Metagenomi just raised $94 million in its initial public offering. It now has enough money to last it for a few years.

This Biotech IPO Stock Just Took a Tumble, But Don't Give Up on It Yet

Mercury Systems

PepGen Inc

Children's Place

RXO Inc

Sana Biotechnology

Tenaya Therapeutic

The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company's shares as he reportedly prepares to move to Florida to take advantage of the better income tax environment.

Insider Buying: Taking a Controlling Stake in a Struggling Retailer?

EMERYVILLE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced the closing of its previously announced initial public offering of 6,250,000 of its common stock at a price to the public of $15.00 per share. The aggregate gross proceeds to Metagenomi from the offering were approximately $93.75 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Metagenomi has granted the underwriters a 30-day option to purchase up to an additional 937,500 of its common stock at the initial public offering price less underwriting discounts and commissions.

Metagenomi Announces Closing of Initial Public Offering

Shares of Metagenomi Technologies , a genetic medicines company backed by Bayer Healthcare and Moderna , slumped 32% in their Nasdaq debut on Friday.

Moderna, Bayer-backed Metagenomi stock drops 32% on Nasdaq debut

Genetic medicines company Metagenomi Technologies MGX.O said on Thursday it is aiming for a valuation of $563 million in its U.S. initial public offering (IPO), a number that is at the low end of its initial target range.

Moderna-backed Metagenomi cuts US IPO valuation target to $563 mln

EMERYVILLE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (“Metagenomi”), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at a price to the public of $15.00 per share. The gross proceeds to Metagenomi from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $93,750,000. All of the shares are being offered by Metagenomi. In addition, Metagenomi has granted the underwriters a 30-day option to buy an additional 937,500 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.

Metagenomi Announces Pricing of Initial Public Offering

News for Metagenomi Inc Stock (MGX)